CIK: 0001910264 · Show all filings
Period: Q2 2025 (← Previous) (Next →)
Filing Date: Aug 14, 2025
Total Value ($000): $461,376 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| ACLX | Arcellx, Inc. | 2,346,630 | $154,526 | 33.5% | $16.72 | +272.4% | Common Stock | 03940C100 |
| SPRY | ARS Pharmaceuticals, Inc. | 4,012,903 | $70,025 | 15.2% | $6.79 | +112.6% | Common Stock | 82835W108 |
| CRSP | CRISPR Therapeutics AG | 1,048,951 | $51,021 | 11.1% | $71.59 | -45.9% | Common Shares | H17182108 |
| ZBIO | Zenas BioPharma, Inc | 4,911,539 | $47,593 | 10.3% | $17.98 | -45.8% | Common Stock | 98937L105 |
| ORIC | ORIC Pharmaceuticals, Inc. | 4,514,929 | $45,827 | 9.9% | $6.71 | 0.0% | Common Stock | 68622P109 |
| MLYS | Mineralys Therapeutics Inc. | 3,127,933 | $42,321 | 9.2% | $14.62 | -0.9% | Common Stock | 603170101 |
| DSGN | Design Therapeutics, Inc. | 6,526,476 | $21,994 | 4.8% | $16.67 | -77.6% | Common Stock | 25056L103 |
| OCS | Oculis Holding AG | 322,500 | $6,260 | 1.4% | $20.50 | -10.4% | Ordinary Shares | H5870P102 |
| ALMS | Alumis Inc. | 1,959,896 | $5,880 | 1.3% | $13.30 | -64.5% | Common Stock | 022307102 |
| NKTX | Nkarta, Inc. | 3,333,333 | $5,533 | 1.2% | $11.49 | -84.1% | Common Stock | 65487U108 |
| ORKA | Oruka Therapeutics, Inc | 430,330 | $4,824 | 1.0% | $33.46 | -68.9% | Common Stock | 687604108 |
| KALA | KALA Bio, Inc. | 598,940 | $2,851 | 0.6% | $6.53 | -40.2% | Common Stock | 483119202 |
| ENGN | enGene Holdings Inc. | 747,750 | $2,722 | 0.6% | $11.04 | -66.0% | Common Shares | 29286M105 |